FY2026 EPS Estimates for Nuvation Bio Cut by HC Wainwright

Key Points

• HC Wainwright cut its FY2026 EPS estimate for Nuvation Bio to a loss of $0.34 per share from a loss of $0.33, while maintaining a Buy rating and $21 price target.
• Nuvation Bio’s latest quarter matched consensus with an EPS loss of $0.12, while revenue of $44.95 million topped the $34.39 million estimate.
• Analyst views are mostly positive, but targets have been trimmed: RBC lowered its target to $17 while keeping an Outperform rating. MarketBeat reports a Moderate Buy consensus rating and a $12.89 average target.

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Equities research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for Nuvation Bio in a research report issued on Thursday, November 5th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.34) for the year, down from their prior estimate of ($0.33). HC Wainwright currently has a "Buy" rating and a $21.00 price target on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio's Q2 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.13) EPS.

Nuvation Bio (NYSE:NUVB - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.12). The firm had revenue of $44.95 million during the quarter, compared to the consensus estimate of $34.39 million. Nuvation Bio had a negative return on equity of 45.69% and a negative net margin of 67.38%.

Other equities analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Nuvation Bio from a "hold" rating to a "sell" rating in a research report on Saturday, October 10th. Royal Bank Of Canada lowered their price objective on shares of Nuvation Bio from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Thursday. Citigroup reiterated a "market outperform" rating on shares of Nuvation Bio in a research note on Monday, October 19th. Wedbush reissued an "outperform" rating and set a $11.00 target price on shares of Nuvation Bio in a research report on Wednesday, September 16th. Finally, Cantor Fitzgerald assumed coverage on shares of Nuvation Bio in a research note on Friday, August 21st. They set an "overweight" rating for the company. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Nuvation Bio presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.89.

Nuvation Bio Stock Performance

NYSE NUVB opened at $4.16 on Monday. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 1.73. Nuvation Bio has a one year low of $3.97 and a one year high of $9.75. The company has a debt-to-equity ratio of 1.23, a current ratio of 7.45 and a quick ratio of 7.30. The business's fifty day moving average is $5.39 and its 200-day moving average is $5.37.

Insider Activity at Nuvation Bio

In related news, insider Gary Hattersley sold 100,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $7.09, for a total value of $709,000.00. Following the completion of the transaction, the insider directly owned 100,000 shares of the company's stock, valued at approximately $709,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 30.11% of the company's stock.

Hedge Funds Weigh In On Nuvation Bio

Hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC purchased a new stake in Nuvation Bio in the 1st quarter worth approximately $2,399,000. Bank of New York Mellon Corp purchased a new position in shares of Nuvation Bio during the 2nd quarter valued at $3,804,000. NewEdge Advisors LLC grew its position in shares of Nuvation Bio by 19.5% during the 2nd quarter. NewEdge Advisors LLC now owns 1,231,733 shares of the company's stock valued at $6,996,000 after purchasing an additional 200,621 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Nuvation Bio during the 2nd quarter valued at $625,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Nuvation Bio by 75.6% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,439,357 shares of the company's stock worth $6,175,000 after purchasing an additional 619,725 shares during the period. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

More Nuvation Bio News

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: IBTROZI revenue grew 18% sequentially. Management also outlined the possibility of European approval in the first half of 2027, which could trigger an approximately $30 million milestone payment. Article: Nuvation Bio outlines potential Europe approval and IBTROZI growth
• Positive Sentiment: Nuvation Bio reported a third-quarter loss of $0.12 per share, while revenue of $44.95 million exceeded analyst estimates cited in the company’s earnings coverage. The loss was narrower than a year earlier. Article: Nuvation Bio reports Q3 loss and revenue
• Neutral Sentiment: H.C. Wainwright reiterated its Buy rating and $21 price target, although it trimmed its Q1 2027 EPS estimate to break-even from $0.01. Article: Nuvation Bio gets a Buy from H.C. Wainwright
• Neutral Sentiment: RBC lowered its price target from $20 to $17 but maintained an Outperform rating. B. Riley also reduced its target, from $14 to $13, while keeping its Buy rating. The lower targets are a cautionary note, though both firms remain positive on the shares. Article: B. Riley adjusts Nuvation Bio price target

Nuvation Bio Company Profile

Nuvation Bio, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with cancer. The company seeks to address areas of significant unmet need, with an emphasis on targeted therapies for solid tumors.

Nuvation Bio's lead product is taletrectinib, a next-generation tyrosine kinase inhibitor designed for patients with ROS1-positive non-small cell lung cancer (NSCLC), including certain tumors that have developed resistance to earlier ROS1-targeted treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.